Since 2006, intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs are being used to treat neovascular age-related macular degeneration (nAMD),[1] diabetic macular edema (DME),[2] retinal vein occlusion (RVO).[3] Repeated intravitreal anti-VEGF drugs are required to significantly improve the visual acuity and visual distortion and are widely concerned by ophthalmologists and patients. This evidence concerns the gene VEGFA and retinal vein occlusion.